H eterogeneity is pervasive in human cancer and manifests as morphological differences between cells or distinct karyotypic patterns, protein and biomarker expression levels and genetic profiles 1, 2 . Tumours are complex ecosystems of malignant cells surrounded by non-malignant stroma, including fibroblasts, endothelial cells and infiltrating immune cells [3] [4] [5] . Intratumour heterogeneity arises through various mechanisms (Fig. 1) . In clonal evolution models, stochastic accumulation of mutations through genomic instability results in increasing genetic diversity, with the tumour acquiring subclones with distinct genotypes over time 6 . Heterogeneity is also generated through cellular differentiation. In cancer stem cell (CSC) models, cancers are hierarchically organized with a stem cell-like population, sustaining tumour growth through self-renewal and differentiation 7 . The tumour microenvironment also generates intratumour heterogeneity by exerting different selective pressures in distinct regions of the tumour [8] [9] [10] [11] . These models are not mutually exclusive and act together to create a complex system with multiple layers of heterogeneity established by the distinct genetic, epigenetic, transcriptomic, proteomic and functional properties of different cells.
Nevertheless, most cancer research and therapy decisions are carried out at the whole-population level. Standard treatment strategies target a single receptor or pathway, treating cancer as a homogenous disease. Even new precision medicine programmes, such as the NCI-MATCH (National Cancer Institute-Molecular Analysis for Therapy Choice) trial, which genetically profiles individual patient tumours to determine the most appropriate targeted therapy, do not consider the number of cells that express the targeted variant and only require it to be detectable above background 12 . This therapeutic approach may fail for many reasons: if the variant is not critical to drive tumour growth or not expressed in the tumour-promoting cell populations; if some cell populations have additional driver or resistance mutations; or if tumour growth, viability or resistance is encoded at the non-genetic level.
However, technologies for interrogating the whole genome, transcriptome, epigenome and proteome in single cells are maturing. Advances in accuracy, throughput, automation, computational analysis and cost provide the potential to profile thousands of cells from an individual tumour. A first goal in cancer is to characterize the extent of intratumour heterogeneity in individual tumours, at various regulatory levels, from genotype to phenotype, and to spatially localize cell populations within tumours. Subsequently, understanding the function and effect of different cell populations on tumorigenesis, including which features promote tumour initiation, progression or drug resistance, will also be key. Functional characterization will be particularly challenging, as there is no clear method for extrapolating cell function from large-scale 'omics' data aside from traditional experimental interrogation. In the long term, new insights may be translated to the clinic, for example, to enable tumour composition analysis for diagnostics and therapeutic assignment, or to identify pre-existing drug-resistant subclones prior to treatment. In this Review, we discuss important technological considerations for experimental designs in cancer research, review single-cell studies that have provided new insights in tumour biology and present open questions for future single-cell applications.
Technological considerations for single-cell studies of cancer
Single-cell technologies have advanced rapidly in the past several years. Currently available protocols vary in cell capture method, library preparation chemistry and throughput (Table 1 ) (reviewed in refs [13] [14] [15] [16] ). Most protocols require single-cell suspension, so the first critical consideration is optimizing tumour dissociation to generate a cell suspension that is fully representative of the intact tumour in terms of cell populations, their frequencies and expression programmes. Digestion of solid tumours eliminates spatial information and can obscure the true programme of individual cells 17, 18 . Although there is no consensus for how to measure these profound effects, cellular diversity after dissociation can be analysed by flow cytometry for known cell types or markers for the specific tumour type. Populations are typically validated by follow-up analyses in situ, but this approach only confirms their existence and does not determine whether all cell populations in the tumour were accounted for after cell dissociation. Ultimately, identification of the same populations using different protocols would increase confidence in the results.
Technologies for transcriptome analysis are the most advanced and have been used to profile CSCs, map differentiation trajectories, describe drug resistance programmes and define the immune infiltrate in tumours [19] [20] [21] . The first single-cell transcriptome technologies utilized microfluidics to capture cells followed by multiplex quantitative PCR (qPCR) for selected genes, but most recent studies favour single-cell RNA sequencing (scRNA-seq) to enable assessment of the entire transcriptome. Selection of the most appropriate scRNA-seq protocol depends on the sample size, the number of cells to be sequenced and whether transcript counting or full-length mRNA sequencing is desired (Table 1) . When large cell Review ARticle | SERIES NaTuRE CEll Biology numbers must be sequenced, high-throughput, semi-automated droplet-based approaches (for example, inDrop 22 and Dropseq 23 ) are optimal. However, these approaches typically achieve lower transcriptome coverage and detect fewer lowly expressed genes, and there is very limited transcript sequence coverage due to 3′ end counting, precluding single-nucleotide variant (SNV) and splicing analyses 17 (Table 1) . Droplet-based protocols are also less amenable to studying small cell numbers, for instance, circulating tumour cells (CTCs), disseminated tumour cells or micrometastases. For such samples, cell isolation by flow cytometry or micromanipulation followed by manual library preparation in microwell plates is more tractable. These protocols typically amplify full-length mRNA by switching mechanism at 5′ end of RNA template (SMART) or alternative chemistries, which enable full-length mRNA sequencing for SNV, splicing and deeper transcriptome analyses [24] [25] [26] [27] . For tissues that are preserved or cannot be readily dissociated, single-nucleus RNA-seq approaches, such as DroNc-seq 28 or microwell-based single-nucleus RNA-seq 29 , may be optimal (Table 1) .
Although less widely utilized, single-cell genome analysis has been used to track clonal dynamics, infer evolutionary trajectories and compare paired primary and metastatic tumours (as detailed below). A major challenge is that the DNA must be massively amplified with minimal error. Several alternative chemistries have been developed for whole-genome amplification, which are alternatively better suited for SNV or copy number variant (CNV) analyses (Table 1) . Another major issue for single-cell genome studies is that, unlike whole-transcriptome approaches in which lower sequencing depth can still provide robust information about cell identity, the genome has a fixed, large size and there is effectively no cheap way to sequence it. Many single-cell studies are beginning to opt for lower breadth and sequence either the whole exome or a targeted panel of genes (reviewed in ref. 15 ). Analysis of single-cell genomic data is also more challenging and less standardized owing to technical errors, such as uneven amplification and allelic dropout. Allelic dropout, in which a particular region of one chromosome is not amplified, is the main technical and analytic challenge 30, 31 . Comparison of whole-genome amplification approaches and selected analytic methods can be found in refs 15, [32] [33] [34] [35] [36] . Protocols to measure other regulatory levels, such as the epigenome and proteome, are developing rapidly, as are multiscale approaches to analyse multiple regulatory levels in the same cell (that is, multi-omics) and methods for spatial analysis in intact tissues. Selected methods are highlighted in Box 1.
genetic heterogeneity and subclonal dynamics
Most tumours comprise subpopulations of cells with distinct genotypes called subclones. Next-generation sequencing data have revealed that a tumour possesses on average over 10,000 somatic mutations: ~2-8 in 'driver' genes that confer a selective growth advantage, and ~30-60 protein-coding changes in 'passenger' genes that may alter other cellular functions 37 . Subclonal diversification arises through genomic instability and numerous mechanisms, including homologous recombination deficiency, chromosome instability, chromothripsis, misregulation of APOBEC enzyme activity and drug treatment 6, [38] [39] [40] [41] [42] [43] [44] [45] [46] . Several models for subclonal diversification have been proposed based on next-generation sequencing data of bulk human tumour samples, the prevailing being linear, branching, neutral and punctuated models (reviewed in ref. 47 ). Most next-generation sequencing studies report branching evolution in human cancers, including leukaemia, breast and liver cancers, colorectal cancer, ovarian cancer, prostate cancer, kidney cancer, melanoma and brain cancer (reviewed in ref. 47 ). Although sophisticated statistical and mathematical models have been developed to infer subclonal dynamics and tumour evolution from bulk data, they rely on major assumptions and cannot extrapolate single-cell genotypes because overlapping mutation frequencies cannot be assigned to the same or different cells, technical errors may yield imprecise mutation frequencies and detection limits preclude identification of rare subclones 15 ( Fig. 2 ). Single-cell genome analyses mitigate many of these limitations and, most importantly, can determine whether mutations are in the same or different cells. This can help to address important questions about subclonal dynamics, such as how specific subclones interact (for example, collaborate versus compete), which subclones can invade and metastasize, how subclonal composition affects clinical outcome and how drug resistance evolves (for example, from pre-existing clones versus the acquisition of new mutations).
Single-cell studies of subclonal heterogeneity have produced new details about subclonal frequencies and their evolution during tumour progression. Single-nucleus sequencing of breast tumours showed that copy number evolution occurred in short bursts early in tumour evolution, whereas point mutations evolved gradually over time to produce more extensive clonal diversity 48 . This 49, 50 . For example, targeted single-cell SNV analysis of patients with acute lymphoblastic leukaemia revealed codominant clones, and showed that KRAS mutations occurred late in disease development but were not sufficient for clonal dominance 49 . In a case study of colon cancer, the dominant clone possessed APC and TP53 mutations typical of colon cancers, but a rare subclone with CDC27 and PABPC1 mutations was also identified 50 . These studies suggest that combinatorial therapies that target multiple subclones may produce better results against polyclonal disease.
A study investigating clonal evolution during breast cancer invasion showed a direct lineage relationship between non-invasive ductal carcinoma in situ and adjacent invasive ductal carcinoma lesions in individual patients with breast cancer using topographical single-cell sequencing 51 . These results indicate that most mutations and CNVs evolved within the ducts prior to invasion, with multiple clones escaping from the ducts and co-migrating into the adjacent tissues to establish invasive carcinomas. These findings contrast with models for cancer cell invasion proposing that distinct clones give rise to in situ and invasive tumour cells [52] [53] [54] , and argue against the notion that extrinsic stimuli (that is, 'field effects') cause multifocal disease.
Single-cell genetic analysis has also provided new insights into the longstanding debate over whether drug resistance is caused by the selection of rare pre-existing clones or through acquired resistance by induction of new mutations. Single-cell DNA sequencing of longitudinal samples from patients with breast cancer before and after neoadjuvant chemotherapy showed that resistant genotypes are pre-existing and selected by chemotherapy 55 . Interestingly, scRNA-seq of the same samples showed that the transcriptome profiles of cells pre-treatment and post-treatment were entirely distinct. Cells with resistant programmes were undetectable before treatment, although subsets of cells expressing individual genes associated with chemoresistance could be identified. These data indicate that chemoresistance is conferred through both genetic selection and induction of new transcriptome programmes.
Single-cell analyses of CTCs have also revealed genetic mechanisms of drug resistance. Studies of CTCs from patients with breast cancer have shown heterogeneity for genes important for diagnosis and therapy response, such as ERBB2 and PIK3CA 56, 57 . Analysis of CTCs from patients with small-cell lung cancer revealed distinct molecular mechanisms for resistance to chemotherapy 58 . CTCs from chemoresistant patients displayed different CNV profiles than CTCs from chemorefractory patients, suggesting a different genetic basis for immediate resistance (chemorefractory) versus delayed resistance (chemoresistant). A classifier was also developed to distinguish between the two types of patients, supporting the application of single-cell genomics for CTC-based diagnostics 58 . There are still several limitations to single-cell genomic analyses that prevent their more general use in experimental and clinical practice. Technical limitations that hinder confident SNV calling due to allelic dropout are a major issue. Understanding of the biological function and clinical importance of specific genetic clones is also lacking. It will be critical to decipher how a single-cell genotype translates into cellular function, how individual clones affect tumour behaviour and how clones interact to promote tumour progression, metastasis and drug resistance. Innovative strategies are needed to address the lack of a universal approach for the isolation of specific genetic clones and experimental interrogation of their function.
Non-genetic heterogeneity and cellular differentiation
ScRNA-seq studies have shown that many normal tissues are maintained by a pool of adult stem cells that differentiate into multiple 'cell types' with distinct 'cell states' distinguished by more subtle differences in differentiation, activation, metabolic state or stage of the cell cycle [59] [60] [61] [62] [63] [64] [65] (Fig. 2c) . Similarly, tumours also contain CSCs, which behave like normal stem cells in their capacity to self-renew, differentiate and propagate the tumour upon transplant (reviewed in ref. 66 ). However, some tumours do not follow this model 67, 68 . One outstanding question is to what degree CSCs and other tumour cell populations maintain the developmental programme of their normal cell counterparts, versus dedifferentiating or assuming an aberrant cell state (Fig. 2d) . Single-cell technologies provide the opportunity to measure cell states in individual cells and map tumour cells onto the normal spectrum of allowable cell types and states of their tissue of origin.
One of the first single-cell studies in cancer used a single-cell multiplex qPCR approach to show that human colon cancers contain distinct cell populations that mirror the cellular lineages of the normal colon 19 . This transcriptional heterogeneity was not due to underlying genetic heterogeneity, as injection of single CSCs into
Box 1 | emerging technologies for single-cell analyses in cancer
Single-cell transcriptome and genome studies have emerged as vital tools for investigating mechanisms of cancer, and more technologies are being adapted to operate in single-cell resolution to explore the disease in ways that were previously unavailable. This is exemplified by several common protocols for epigenetic analysis that now can be performed at the single-cell level, including DNase-seq 136 and ATAC-seq 137, 138 for defining regions of open chromatin, Hi-C for investigation of chromosomal contacts 139 , ChIP-seq for histone position mapping 140 , bisulfite sequencing (single-cell bisulfite-seq) 141 or bisulfite-free methods (single-cell CGI-seq) 142 for measuring DNA methylation state, and CLEVERseq 143 and scAba-seq 144 to measure active DNA demethylation by 5-fluorocytosine sequencing and 5-hydroxymethylcytosine sequencing, respectively. Multiscale analysis of multiple regulatory levels in the same cell is also an area of rapid development and provides the potential to comprehensively understand how and why malignant cells produce a particular phenotype, function or behaviour. Combinatorial methods currently exist for analysis of the genome and transcriptome (G&T-seq and DR-seq) [145] [146] [147] , epigenome and transcriptome (scMT-seq, scTrio-seq and scN-MT-seq) [148] [149] [150] , and techniques for studying the proteome and transcriptome are in development 151, 152 . Single-cell proteomics are another area of paramount interest as protein expression is the ultimate functional output of the cell. Although there are no commercial methods for whole-proteome level analysis, several technologies for high-parameter protein analysis in single cells have been developed. Time of flight mass cytometry (CyTOF), which utilizes heavy metal-conjugated antibodies to quantify protein expression by time-of-flight inductively coupled plasma mass spectrometry, can theoretically multiplex up to 135 parameters in single cells [153] [154] [155] . The co-detection by indexing (CODEX) platform also enables high-parameter protein expression analysis using an in situ polymerization-based indexing procedure and fluorescently barcoded antibodies 156 . This provides the added advantage of spatial localization of cell populations within the native tissue context. Spatial genomics technologies for singlecell analysis, such as FISSEQ Review ARticle | SERIES NaTuRE CEll Biology immune-deficient mice gave rise to monoclonal tumours as heterogeneous as the parental one. A study of human oligodendroglioma using scRNA-seq 20 showed that tumours were composed of astrocyte-like and oligodendrocyte-like cells and a rare subpopulation of undifferentiated cells resembling neural stem cells. Similar to the colon cancer study, CNV and SNV analysis showed that each subclonal lineage displayed similar hierarchies. Both studies found differences in the tumour cells relative to their normal counterparts. The table shows the frequency of each detected mutation. The panels show three (of many) possible clonal trajectories that can be inferred. The nodes represent points at which a mutation occurred, and overlapping coloured regions indicate that each of the mutations is present within any cell that is part of that population. b, Challenges associated with deciphering the genotype of a metastatic founder clone and subclonal trajectories from bulk genome sequencing of paired metastatic and primary tumours. The table shows the observed mutation frequencies in an example experiment in which a metastatic tumour from the individual in a was sequenced. The panels show three possible explanations for the observed frequencies. c, Cell types and states found in normal tissues. Tissues comprise different mature 'cell types' (labelled 1-5), which carry out specified functions. Cells within a 'type' can exist in a spectrum of allowable 'cell states' depending on the physiological status of the tissue. Mature cell types are derived from stem cells through a series of discrete differentiation intermediates or progenitors. The circles represent single cells, and the colour clouds represent the spectrum of allowable states. The density of circles represents the probability of observing a cell with that phenotype in a scRNA-seq experiment. d, Tumour cell types and states differ from normal tissue. Single-cell studies have shown that tumours contain stem-like cells (CSCs) and that differentiation is often noisy, skewed towards specific cell lineages.
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In the oligodendroglioma study, the two glial lineages seemed to originate from the stem cell-like population, without the discrete differentiation intermediates observed in the normal tissue. Rather, a continuum of differentiation profiles was observed along each lineage, indicating that tumour cells may exist in more dynamic and less discrete differentiation states than normal cells 20 (Fig. 2d) . Another study of oligodendroglioma showed that progression to more advanced stages was associated with expansion of primitive cells, with tumours bearing less similarity to the cellular composition of normal tissues 69 . However, the lack of normal cell population profiling in these studies makes it difficult to discern how similar each population was to its healthy counterpart. Likewise, in the colon cancer study 19 , several cell subpopulations typical of the normal colon were absent in the tumours, suggesting that there was a skewing or block in normal differentiation 19 (Fig. 2d) . Single-cell studies of acute myelogenous leukaemia (AML) have shown similar alterations in normal differentiation. A mouse model of AML was shown to contain two cell types: one resembling granulocyte/monocyte progenitors and the other macrophage and dendritic cells 70 . Normal and leukaemic counterparts showed significantly different gene network modules, suggesting an aberrant programme in leukaemic cells. Altered myeloid differentiation has also been observed in human paediatric AML by single-cell mass cytometry. In one report, two alternative approaches, PhenoGraph and statistical analysis of perturbation response (SARA), were used to compare signalling programmes in normal haematopoietic and leukaemic cells 71 . Although both primitive and mature monocytelike cells were identified in all patients, they displayed different degrees of aberrant myeloid differentiation, which did not correlate with the cell-surface marker phenotype. In AML, enumeration of primitive CD34 + /CD45 low blasts is often used for clinical diagnosis and classification of leukaemias 72 . This study showed that intrinsic signalling programmes were often decoupled from the cellsurface phenotype, challenging the standard diagnostic approach. Many patients possessed CD34
-leukaemic cells displaying primitive signalling programmes, and the percentage of primitive cells rather than cell-surface phenotype was more predictive of overall survival 71 . These studies suggest that cancer cells often resemble normal cell types and states, but acquire aberrant programmes and display skewed differentiation towards more restricted lineages than their tissue of origin. Defining the aberrant programmes in single cells with relevance to stability and plasticity may reveal new mechanistic insight and therapeutic targeting strategies.
Heterogeneity in diagnostics and therapy response
Mechanisms of drug response have also been studied at the single-cell level. CTCs have been a major focus as they offer a noninvasive window into tumour response. One study reveals that the majority of patients with prostate cancer with varying stages of disease and resistance to androgen deprivation therapies harboured CTCs with at least one type of androgen receptor alteration 73 . Furthermore, patients on the second-line androgen receptor inhibitor enzalutamide (administered after the development of resistance to androgen deprivation therapy) often had CTCs with activated non-canonical Wnt signalling, showcasing how different mechanisms for generating non-genetic heterogeneity can produce drug resistance, and that tracking this through assaying CTCs is clinically feasible.
Single-cell mass cytometry has also been used to measure differential responses to chemotherapy in patients with AML. The percentage of proliferating stem and progenitor-like leukaemic cells was shown to be significantly correlated with therapy response, in addition to signalling abnormalities in primitive AML cell populations 74 . Patients with clinically favourable subtypes of AML demonstrated a higher fraction of cells in S-phase than other subtypes.
This suggests that the quiescent state facilitates cancer cell protection and survival during therapy. In another study, chemotherapy increased phenotypic diversity away from traditional stem cell phenotypes in patients with AML 75 . This finding contrasts with classic resistance models that suggest selection of a more primitive cell population during treatment results in outgrowth of a more uniform population.
ScRNA-seq has also shown how standard diagnostic bulk tumour profiling can mask clinically relevant heterogeneity. Glioblastomas can be stratified into four distinct subtypes based on their mRNA expression signature: proneural, neural, classical and mesenchymal 76 . Interestingly, scRNA-seq analysis showed that glioblastomas contain cells that resemble each of the four subtypes, even though this is not observed in bulk analyses. Increased intratumour heterogeneity was also associated with decreased survival, perhaps because of improper patient stratification and treatment assignment, or enhanced genomic instability, tumour evolution or resistance 77 . Single-cell analyses may also eventually be valuable for predictive diagnostics. Single-cell analysis of targeted transcriptome (SCATTome), which predicts drug response for individual cells based on transcriptome signatures using an assortment of machine learning methods, was able to predict response to proteasome inhibitor treatment in patients with multiple myeloma 78 . Despite these new discoveries, several limitations of single-cell analyses are worth further consideration. As in single-cell genome studies, assigning function to cell populations is the biggest challenge for most non-genetic single-cell studies. Gene ontology and gene set enrichment analyses can provide clues for signalling pathways that are overrepresented in a cell population, but most of these tools are developed for bulk transcriptome analysis and handle missing data poorly (reviewed in refs 79, 80 ). As most scRNA-seq protocols only detect 10-40% of the transcriptome, they are not optimal for studying lowly expressed genes, such as those encoding transcription factors, or for the investigation of specific signalling pathways. Dropout of signalling intermediates makes determining whether a pathway is activated challenging. It is also often difficult to determine what constitutes a true cell population, as slight changes in clustering parameters can produce different results. How to decide what represents a cell type versus a cell state continues to be a major debate in the field, particularly for rare cell populations, which may represent cells transiently switching from one state to another or true rare cell types. The only way to assign function to a cell population is through conventional experimentation, which most single-cell reports lack. It is also important to consider that tumour behaviour is probably more than just the sum of its individual cell parts, with different cell populations synergizing or collaborating to take on new macroscale functions and behaviours that are not observable using reductionist approaches. If so, new integrated informatic, experimental and modelling approaches for analysing single cells will be necessary to truly understand tumour behaviour.
Heterogeneity and metastasis
Metastasis remains the cause of most patient mortality and continues to be challenging to treat clinically and investigate experimentally. The general dogma is that metastasis is carried out by rare cells with unique cellular and molecular properties 81 . Single-cell investigations now enable the identification and characterization of such cells, including their localisation in primary tumours, and the effect of genetic versus non-genetic and intrinsic versus extrinsic factors on metastasis (Fig. 3) .
Next-generation sequencing studies of bulk tumour samples indicate that metastasis is initiated by a subclone of the primary tumour. In one study, whole-genome sequencing identified numerous point mutations and small indels represented in higher frequencies in the brain metastatic tumour than in the paired primary breast . Similar disparities in mutation frequencies have been reported in paired tumours and metastases from patients with pancreatic and renal cancers, in which the metastasis founder subclones localized to a specific region in the primary tumours, supporting a subclonal model for metastasis initiation 83, 84 . One confounding issue in these studies is that the metastases often possessed unique mutations that were not found in paired primary tumours 83 . This makes it challenging to infer the genotype of the original metastasis founder cells, because it is not clear whether the metastasisexclusive mutations were present in the primary tumour below the limit of detection or whether they arose after metastatic seeding via parallel evolution (Fig. 2b) .
Single-cell genome studies of metastasis are beginning to resolve these challenges. Early single-cell studies of metastasis focused on disseminated tumour cells in the bone marrow of patients with breast cancer, and found that these cells disseminate early in tumour evolution by karyotype and subchromosomal variant analyses 85, 86 . This is corroborated by reports showing that metastatic lesions similarly derive from early dissemination events 87, 88 . Other single-cell genetic methods have generated contradictory findings. A singlecell CNV analysis of breast cancer metastasis showed that a single clonal expansion formed the patient primary tumour and seeded its metastasis 89 . Single-cell CNV and SNV analysis in patients with colon cancer showed monoclonal metastatic seeding in one patient and polyclonal in another 90 . The authors of that study also concluded that metastasis occurred late in primary tumour evolution in both patients, as the metastases harboured all of the trunk mutations that were present in the primary tumour cells [85] [86] [87] [88] [91] [92] [93] . Single-cell genomic analyses also provide evidence for collective cell migration as a mechanism for cancer cell invasion.
Topographical single-cell sequencing analysis showed that multiple clones co-migrated through the basement membrane of breast ducts and into adjacent tissues to establish invasive breast carcinomas 51 . This is consistent with previous work showing collective cell migration at the invasive front of tumours, as well as observations that CTC clusters in the bloodstream are more effective than single CTCs for seeding metastasis [94] [95] [96] . Single-cell genome analyses of patient CTCs also provide insight into the genotype of potential metastasis-initiating cells. CTCs display substantial subclonal diversity, suggesting that cells of various genotypes are capable of entering the circulation 97 . This includes very rare subclones, as CTCs from patients with colon cancer were reported to carry SNVs that were only present in the paired primary tumours at very low frequencies 98 . Another study found that CTCs in patients with breast cancer often possess variants that are not found in the primary tumour, indicating that they either represent a rare subclone or occur after dissemination 57 . Importantly, the CTCs were heterogeneous for mutations in two common breast cancer drug targets, ERBB2 and PIK3CA, so identifying which CTCs subsequently produce metastases has direct clinical relevance.
As it is clear that metastatic propensity is not encoded exclusively at the genetic level (reviewed in ref. 99 ), it will be necessary to investigate other programmes (for example, transcriptomic and epigenetic) driving metastatic progression at single-cell resolution. Single-cell multiplex qPCR technology has shown that metastasis is initiated by cells with stem cell and epithelial-mesenchymal transition-like characteristics in patient-derived xenograft models of breast cancer 100 . This is consistent with results from the MMTVPyMT breast cancer mouse model showing CSCs as the origin of metastasis 101 , as well as reports implicating stem cell and Review ARticle | SERIES SERIES | Review ARticle NaTuRE CEll Biology epithelial-mesenchymal transition programmes in other breast cancer models 93, 102 . A recent scRNA-seq study of human head-andneck cancers further implicated epithelial-mesenchymal transition in metastasis 103 . Future studies should utilize single-cell technologies as a new opportunity to investigate other major outstanding questions about metastatic progression, such as what drives metastatic latency and reawakening, how metastatic cells interact with their microenvironment and how they develop resistance to antitumour immunity.
Heterogeneity in the microenvironment
The cellular composition of the tumour microenvironment is critical for disease progression and patient prognosis 104 and changes dramatically during tumorigenesis due to increased angiogenesis, tumour-associated inflammation and fibrosis 8 . Emerging singlecell tools bear great potential to profile the individual cell types comprising the tumour ecosystem, to determine how they differ from normal homeostasis and to reconstruct feedback mechanisms mediating cell-to-cell communications between tumour and stromal cells (Fig. 1) .
A fundamental caveat in bulk cancer genomic analyses (for example, The Cancer Genome Atlas) is that the differences in transcriptomic signatures between tumours may arise due to differential infiltration of immune and other stromal cell types rather than differences in the tumour cells. This can be addressed with analyses at single-cell resolution. Indeed, scRNA-seq analysis has revealed that the bulk transcriptome differences between oligodendroglioma and astrocytoma driven by mutant IDH are primarily due to alterations within stromal macrophage and microglial populations 69 . Another study matched the transcriptomes of non-malignant cells to cell-type-specific expression profiles and inferred the signalling dialogue between cancer cells and their microenvironment 21 . This revealed distinct patterns of exhaustion or activation of tumourinfiltrating T cells in some tumours, suggesting they may exhibit differential responses to immunotherapies 21 . Breakthroughs in cancer immunotherapy have sparked intensive research into tumour-immune cell interactions using genomic tools, and single-cell analysis pipelines will be instrumental in these approaches 105 . ScRNA-seq analysis of human metastatic melanoma revealed specific homeostatic modules in monocytes and dendritic cells within the tumour microenvironment 106 . A recent systemslevel approach using single-cell mass cytometry demonstrated that engagement of systemic and peripheral immunity is critical for tumour rejection after immunotherapy 107 . Future approaches would need to dissect the specificity of anti-tumour immunity before and after checkpoint inhibition, for example, using single-cell V(D)J sequencing to identify the T cell and B cell clones associated with anti-tumour immunity 108 . Direct comparison of single-cell expression signatures from stromal cells in the tumour microenvironment to those in other physiologically similar conditions (for example, inflammation or wound healing) will also determine whether the tumour context induces changes within the normal spectrum of states that a cell may adopt under different conditions or whether cells assume an aberrant tumour microenvironment-specific programme that is not found in normal physiological contexts (Fig. 3c,d ).
Future directions
Given its effect on tumour behaviour and clinical outcome, measurements of intratumour heterogeneity should be increasingly incorporated into standard clinical practice. Single-cell targeted DNA sequencing has been commercialized for cancer diagnostics in AML 109 . In addition, commercial scRNA-seq platforms are simple, automated and fast enough to be immediately amenable for diagnostic applications. The continuous release of higher-throughput sequencers will also continue to drive cost down 110 . Thus, the main hurdles to clinical implementation will probably be upstream and downstream of the single-cell technology itself. First, analysis of single-cell sequencing data requires computational skill, so pipelines for demultiplexing, alignment and cell population analysis should be packaged into software and integrated into instrumentation in a single workflow. Furthermore, we lack automated instrumentation or consensus protocols to generate single-cell suspensions from an excised tumour without human intervention. Typical laboratory workflows are manual, low-throughput and not sufficiently reproducible for clinical application. Third, sampling bias is a notable hindrance and it may be necessary to catalogue whole tumours for accurate assessment of heterogeneity. In many cases, only small biopsies are available or patients are pre-treated with neoadjuvant therapies before sample procurement, which may alter the cellular composition of the tumour. However, the main hurdle to clinical implementation will be data interpretation. To harness the power of single-cell assessment of intratumour heterogeneity beyond descriptive cataloguing, we need to first elucidate the biological and clinical functions of different cell populations and develop new ways to specifically target them.
